Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2023-06.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
E-Type Prostaglandin Therapy for Neonatal Cyanotic CHD.

Journal of the Korean Pediatric Society 1990;33(1):59-65.
Published online January 31, 1990.
E-Type Prostaglandin Therapy for Neonatal Cyanotic CHD.
Ah Young Yun, Jeong Yeon Choi, Yong Soo Yoon
Department of Pediatrics, College of Medicine, Seoul National University, Seoul, Korea
신생아의 청색증 심질환에서 E-type Prostaglandin 치료에 대한 임상적 연구
윤아영, 최정연, 윤용수
서울대학교 의과대학 소아과학교실
Received: 17 May 1989   • Accepted: 12 September 1989
Between December 1987 and November 1988, Twenty infants with ductus-dependent congenital heart disease received intravenous infusion of PGE1 in the pediatric department of Seoul National University Hospital. Nineteen infants had cyanotic congtenital heart diseases and one had severe coarctation of aorta. Fifteen infants responded to PGE1 treatment and the mean Pa02 increased from 24 mmHg to 40 mmHg within one hour of infusion. Seven infants with preinfuson PaO2 less than 20 mmHg showed a greater increase in PaO2 than those with preinfusion PaO2 was one of the determinant of respon- siveness to PGE1. Pyrexia was the most common adverse effect of PGE1. Apnea occurred in 5 infants, 4 of whom were receiving PGE1 at a rate of 0.1 ug/kg/min. With infusion rate under 0.02 ug/kg/min, no serious side effects occured. We recommend the starting dose of PGE1 is 0.05 ug/kg/min and the dose should be reduced if increased PaO2 is maintained.
Key Words: Ductus dependent CHD, E-type prostaglandin

METRICS Graph View
  • 663 View
  • 4 Download

Close layer
prev next